Business news – Page 12
- 
      
        
      
      
     - 
      
        
      
      BusinessAddressing the saga of nitrosamine contamination in drugs
Scientific and regulatory progress is helping minimise the impact of mutagenic impurities
 - 
      
        
      
      
     - 
      
        
      
      ArticleLab Innovations 2023 lays the path for smart and sustainable labs
The UK’s only trade fair for the whole lab industry forges the way to sustainability and innovation
 - 
      
        
      
      BusinessPositive trial sets stage for therapeutic use of MDMA in US
Hallucinogen-assisted psychiatric treatment heads to regulators, amid cost and other concerns
 - 
      
        
      
      BusinessTornado at Pfizer plant accentuates US drug shortage issues
Perennial problem will not be addressed without major reforms to drug market
 - 
      
        
      
      BusinessLapsed US chemical security programme leaves facilities vulnerable
Chemical Facility Anti-Terrorism Standards’ expiry means rules will not be enforced, and companies cannot vet new staff
 - 
      
        
      
      NewsEuropean intellectual property system ready for gene-edited crops
Updates to New Genomic Technology regulations irrelevant to IP say experts
 - 
      
        
      
      FeatureThe drug developers fighting the antibiotic resistance problem
Andy Extance talks to the researchers innovating across different drug classes in the hunt to develop new treatments
 - 
      
        
      
      OpinionResistant to change
Curbing industrial practices that drive antimicrobial resistance needs tighter regulation and enforcement
 - 
      
        
      
      BusinessHow can we maintain the effectiveness of existing antimicrobials?
Reducing environmental pollution and tackling quality issues to stave off resistance
 - 
      
        
      
      FeatureWho will pay for new antibiotics?
Governments around the world are starting to consider alternative funding models and incentives for antibiotics. Katrina Megget asks if it is enough
 - 
      
        
      
      OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
 - 
      
        
      
      FeatureCharting the rise in antimicrobial resistance
We look at the data behind antibiotic drug discovery and development, bacterial resistance and the financial problems with the current business model
 - 
      
        
      
      ArticleCPHI Barcelona 2023: forging collaborations for a promising future in the pharmaceutical sector
CPHI creates connections and inspires partnerships across the global pharma community
 - 
      
        
      
      OpinionCould cheap CRO rates threaten to destabilise biotech?
Pharmaceutical pipelines are heavily dependent on contract research organisations; we can’t afford for them to fail
 - 
      
        
      
      BusinessFines upheld for Advanz Pharma over thyroid drug price increases
UK competition tribunal rules liothyronine pricing ’excessive’ and ‘deliberate’
 - 
      
        
      
      OpinionNavigating the literature torrent
It’s humanly impossible to filter and read everything worthwhile – let’s embrace assistance
 - 
      
        
      
      BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
 - 
      
        
      
      BusinessBiogen to cut 1000 more jobs by 2025
Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion